Biotech Turnaround Fund (BTF)
7
19M
3
0.33
0.57
1
- Stages of investment
- Areas of investment
Summary
Biotech Turnaround Fund (BTF) appeared to be the VC, which was created in 2000. The leading representative office of defined VC is situated in the Bloemendaal. The company was established in Europe in The Netherlands.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Medical Device, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Genizon BioSciences, CymaBay Therapeutics.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Biotech Turnaround Fund (BTF), startups are often financed by MVI Finance, HBM Healthcare Investments AG, Carnegie Asset Management. The meaningful sponsors for the fund in investment in the same round are HBM Healthcare Investments AG, Investissement Desjardins, MVI Finance. In the next rounds fund is usually obtained by HBM Healthcare Investments AG, MVI Finance, BioFund Management.
Considering the real fund results, this VC is 6 percentage points less often commits exit comparing to other organizations. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2003. The usual things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Biotech Turnaround Fund (BTF) works on 15 percentage points less the average amount of lead investments. The top amount of exits for fund were in 2014.
Investments analytics
Analytics
- Total investments
- 7
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.33
- Follow on index
- 0.57
- Investments by industry
- Biotechnology (6)
- Genetics (5)
- Medical Device (4)
- Life Science (4)
- Pharmaceutical (3) Show 3 more
- Investments by region
-
- Canada (5)
- United States (2)
- Peak activity year
- 2001
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 25
- Group Appearance index
- 1.00
- Avg. company exit year
- 23
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| CymaBay Therapeutics | 29 Aug 2003 | Biotechnology, Pharmaceutical, Biopharma | Early Stage Venture | 27M | United States, California, Hayward |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.